Source link : https://newshealth.biz/health-news/fda-oks-subcutaneous-lecanemab-for-early-ad/
After 18 months of intravenous administration of lecanemab (Leqembi), patients may now transition to subcutaneous delivery using the Leqembi Iqlik autoinjector. Medscape Medical News Source link : https://www.medscape.com/viewarticle/fda-oks-subcutaneous-lecanemab-maintenance-dosing-early-ad-2025a1000n3r?src=rss Author : Publish date : 2025-09-02 14:05:00 Copyright for syndicated content belongs to the linked Source.
The post FDA OKs Subcutaneous Lecanemab for Early AD first appeared on News Health.
—-
Author : News Health
Publish date : 2025-09-02 14:05:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8